Community Direct DX, Scienetix, and Advanta Genetics R&D combine with $30 million in funding to create a vertically integrated PCR testing platform.
Three molecular testing companies have merged to form OSPRI, a biotechnology company focused on PCR-based infectious disease detection that aims to provide end-to-end laboratory solutions for healthcare providers.
Community Direct DX, Scienetix, and the R&D division of Advanta Genetics completed the merger with up to $30 million in strategic funding from Catalio Capital Management. The McKinney, Texas-based company positions itself as one of the first fully vertically integrated molecular testing platforms, offering services from assay development through manufacturing, lab buildout, revenue cycle mpanagement, and regulatory support.
OSPRI targets healthcare segments including women’s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories. The company’s platform enables providers to operate high-complexity labs in-house rather than sending samples to external reference laboratories.
“PCR testing is foundational for infectious disease detection, but cost and complexity have kept it out of reach for many,” says Steve M Sorey, partner at OSPRI, in a release. “To unlock widespread adoption, we must reduce both. At OSPRI, we’re obsessed with doing more with less—making PCR faster, cheaper, and better for everyone involved.”
Performance Claims and Testing Capacity
OSPRI claims its technology delivers a 20% to 50% reduction in overall testing costs, 50% to 70% decrease in testing time and workflow steps, and up to a four times increase in testing capacity compared to traditional PCR methods. The company offers a menu of more than 80 PCR tests covering 250-plus pathogens and antimicrobial resistance genes.
The merged entity currently processes over 40,000 tests per day and serves clients across 20 states.
OSPRI’s scientific leadership includes Dr Rahul Sharma as chief science officer, Dr Sadia Almas as chief innovation officer, and Dr Alaina Vincent as chief clinical officer.
Expansion Plans and Market Strategy
The company plans to expand its R&D team by 40% and grow commercial operations by 25% over the next 12 to 24 months. Community Direct DX, one of the founding entities, has launched more than 60 labs nationwide since 2015.
“OSPRI delivers a powerful solution for physician groups and laboratories—simplifying infectious disease testing while creating strong clinical and commercial value,” says Jonathan Blankfein, partner at Catalio, in a release.
The merger combines Community Direct DX’s laboratory deployment experience with Scienetix’s molecular bioengineering expertise and Advanta R&D’s genomics capabilities. Advanta R&D has previously contributed to national public health initiatives.
“Innovation should be accessible—not exclusive,” says Vincent in a release. “Our goal is to enable better, faster care for more patients by equipping providers with the tools they need to lead.”
Photo credit: OSPRI leadership
Photo credit: OSPRI
